echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Defend against South African variants!

    Defend against South African variants!

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Moderna recently stated that it has produced an updated version of the COVID-19 vaccine, which is designed to better protect against the B.


    The vaccine candidate for COVID-19, known as mRNA-1273.


    Moderna said it plans to evaluate the other two enhance the immune methods of force, in order to enhance immunity to resist SARS-CoV-2 mutation.


    immunity

    In addition to this strengthening strategy, the company also stated that it plans to use mRNA-1273.


    In addition, Moderna said it will evaluate the immunogenicity and safety of mRNA-1273.


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.